Stargardt's Macular Dystrophy

Stem cells from bone marrow and human embryos are being investigated as possible treatments for Stargardt's Macular Dystrophy. Click on the link provided to find out more about each trial. It remains too early to know which approach will be most suitable. We need evidence collected in clinical trials to determine if a proposed stem cell treatment is both safe and effective.

tagged as Stargardt's Macular Dystrophy

  • Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy Location: South Korea
    Overview: This trial is investigating the feasibility of transplanting Retinal Pigment Epithelial (RPE) cells made from human embryonic stem cells in cases of Stargardt's Macular Dystrophy. The trial is being conducted at the CHA Bundang Medical Center in Gyeonggi-do, Republic of Korea. Participants will undergo retinal transplantation of approximately 50,000 RPE cells and will be assessed for complications (including tumour formation) and for evidence of engraftment of the transplanted cells. The trials plans to recruit three subjects with Stargardt's syndrome by December 2014.
    Link to Clinical Registry
    Trial Design: Safety Study
    Status: Not yet started
    Stem Cell: Embryonic Stem Cells
  • Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells in Patients With Stargardt's Macular Dystrophy Location: UK
    Overview: This trial is designed to evaluate the safety and effectiveness of transplanting retinal pigment epithelial cells (RPE) in patients with Stargardt's Macular Dystrophy. The trial is being conducted at NHS Lothian Princess Alexandra Eye Pavillion in Edinburgh and Moorefields Eye Hospital NHS Foundation Trust in London, in conjunction with Advanced Cell Technology. Participants will receive different doses of the RPE cells, which have been made from human embryonic stem cells. Participants will be monitored for complications including infection and tumour growth, as well as structural evidence of successful engraftment and changes to vision. The trial expects to enrol 16 subjects by January 2014.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Embryonic Stem Cells
  • Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With Stargardt's Macular Dystrophy Location: US
    Overview: This trial is designed to evaluate the safety and effectiveness of transplanting retinal pigment epithelial cells (RPE) in patients with Stargardt's Macular Dystrophy. The trial is being conducted at Jules Stein Eye Institute, UCLA School of Medicine in California, Bascom Palmer Eye Institute in Florida, Wills Eye Institute-Mid Atlantic Retina in Philadelphia, in conjunction with Advanced Cell Technology. Participants will receive different doses of the RPE cells, which have been made from human embryonic stem cells. Participants will be monitored for complications including infection and tumour growth, as well as structural evidence of successful engraftment and changes to vision. The trial expects to enrol 16 subjects by July 2013.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Embryonic Stem Cells